What plant does Tagitinin C come from?

Tagitinin C is isolated from Tithonia diversifolia, a flowering plant in the Asteraceae family commonly called the Mexican sunflower or tree marigold. The compound belongs to the germacranolide subclass of sesquiterpene lactones and is found predominantly in the leaves and aerial parts of the plant, which has a long history of ethnomedicinal use in Africa and Asia.

How effective is Tagitinin C against Trypanosoma brucei?

In vitro studies (PMID: 29146170) showed Tagitinin C exhibits anti-trypanosomal activity against Trypanosoma brucei that significantly surpassed the reference drug suramin under the tested conditions. This activity is attributed to its alpha-methylene-gamma-lactone group, which alkylates critical thiol-containing proteins in the parasite's metabolic machinery. However, no animal or human studies have confirmed whether this potency translates to in vivo efficacy or adequate safety margins.

Can Tagitinin C inhibit cancer cell growth?

Tagitinin C demonstrates proteasome inhibitory activity in vitro, meaning it can suppress the 20S proteasome complex that cancer cells rely on for clearing misfolded proteins and regulating cell cycle proteins like p53 and cyclins. This mechanism is pharmacologically similar to the approved drug bortezomib, though Tagitinin C acts covalently via its lactone moiety rather than through boronate ester chemistry. All anticancer evidence remains at the cell culture stage, and no clinical or animal tumor model data have been published establishing efficacy or dosing in oncology contexts.

Is Tagitinin C safe to take as a supplement?

Tagitinin C is not currently available as a standardized dietary supplement, and no safe human dosage has been established through clinical trials or formal toxicology studies. Its alpha-methylene-gamma-lactone structure raises concern for contact sensitization and potential cytotoxicity at higher concentrations, a liability common to sesquiterpene lactones as a chemical class. Individuals with allergies to Asteraceae family plants should exercise particular caution, and use during pregnancy or breastfeeding is not advisable given the absence of safety data.

What is the difference between Tagitinin C and other sesquiterpene lactones like parthenolide?

Both Tagitinin C and parthenolide share the alpha-methylene-gamma-lactone pharmacophore responsible for their electrophilic bioactivity, but they differ in core skeleton: parthenolide is a germacranolide with an epoxide group that inhibits NF-kB by alkylating IKKβ, while Tagitinin C is a germacranolide whose primary documented targets are trypanosomal machinery and the 20S proteasome. Parthenolide has substantially more published preclinical and some clinical data, including studies in leukemia and migraine, whereas Tagitinin C research remains sparse and early-stage. This makes parthenolide a more thoroughly characterized reference compound within the same lactone subclass.

What does current research show about Tagitinin C's effectiveness in human studies?

Current evidence for Tagitinin C is primarily limited to in vitro (test tube) and preliminary animal studies, particularly regarding its anti-trypanosomal and proteasome-inhibitory effects. While these laboratory results are promising—showing stronger anti-trypanosomal activity than the clinical reference drug suramin—human clinical trials are needed to establish safety and efficacy in real-world conditions. Most research remains in early-stage development, and no large-scale human studies have been completed as of now.

Who would benefit most from Tagitinin C supplementation based on current research?

Based on preliminary evidence, potential beneficiaries might include individuals researching natural anti-parasitic compounds, though clinical validation is lacking. The compound's proteasome-inhibitory activity suggests theoretical interest for those exploring cancer-related research, but this remains experimental. Because evidence is limited to in vitro studies, Tagitinin C should not be considered an established therapeutic for any specific population without further human research.

Are there known limitations or gaps in understanding Tagitinin C's bioavailability as a supplement?

Bioavailability data for Tagitinin C in human supplementation is extremely limited, with most knowledge derived from in vitro studies rather than absorption and metabolism studies in living organisms. As a sesquiterpene lactone, it likely faces challenges common to this compound class, including potential poor oral absorption and hepatic metabolism, but specific pharmacokinetic data is unavailable. Until oral bioavailability and optimal delivery forms are established through research, the practical effectiveness of Tagitinin C as an oral supplement remains unclear.

Tagitinin C

Tagitinin C is a sesquiterpene lactone derived from Tithonia diversifolia, characterized by an alpha-methylene-gamma-lactone pharmacophore that drives its bioactivity. It exerts potent anti-trypanosomal, proteasome-inhibitory, and anti-ulcer effects primarily through electrophilic alkylation of biological nucleophiles.

Category: Compound Evidence: 2/10 Tier: Emerging

Origin & History

Tagitinin C is a sesquiterpene lactone found in the plant Tithonia diversifolia, commonly known as Mexican sunflower. It is isolated through bioassay-guided fractionation of methanolic leaf extracts using advanced techniques like HPLC-ESI-MS/MS and NMR.

Historical & Cultural Context

Tithonia diversifolia, the source of Tagitinin C, has been used in tropical traditional medicine for treating malaria and various diseases. However, specific historical uses for Tagitinin C itself have not been documented.

Health Benefits

• Potent anti-trypanosomal activity against Trypanosoma brucei, significantly more effective than suramin reference (PMID: 29146170, in vitro evidence).
• Shows proteasome inhibitory activity, suggesting potential in cancer therapy (in vitro evidence).
• Exhibits anti-ulcer effects through mechanisms involving nitric oxide and prostaglandins (preliminary evidence).
• Potential for structural modifications in drug discovery due to α-methylene-γ-lactone and α,β-unsaturated ketone moieties (theoretical basis).
• Selectivity over mammalian cells in anti-trypanosomal assays, indicating lower toxicity (in vitro evidence).

How It Works

Tagitinin C's alpha-methylene-gamma-lactone moiety acts as a Michael acceptor, covalently alkylating cysteine residues in proteasomal subunits, thereby inhibiting the 20S proteasome and disrupting cancer cell protein degradation pathways. Against Trypanosoma brucei, it likely targets thiol-dependent enzymatic systems such as trypanothione reductase, disrupting the parasite's unique redox defense. Its anti-ulcer mechanism is proposed to involve modulation of prostaglandin synthesis and cytoprotective mucosal pathways, though the precise molecular targets remain under investigation.

Scientific Research

Currently, there are no human clinical trials or meta-analyses available for Tagitinin C. All existing evidence is derived from in vitro studies, such as the one reported in PMID: 29146170.

Clinical Summary

Current evidence for Tagitinin C is limited entirely to in vitro and preclinical studies, with no published human clinical trials as of 2024. In vitro anti-trypanosomal assays demonstrated activity against Trypanosoma brucei significantly exceeding that of the reference drug suramin (PMID: 29146170), though specific IC50 comparisons require consultation of the primary source. Proteasome inhibitory activity has been documented in cell-based assays, positioning Tagitinin C as a candidate scaffold for anticancer drug development, but no animal toxicology or efficacy data in cancer models has been widely replicated. The anti-ulcer effects derive from plant extract studies of Tithonia diversifolia rather than isolated Tagitinin C, making compound-specific attribution preliminary.

Nutritional Profile

Tagitinin C is a pure bioactive sesquiterpene lactone compound (germacranolide-type), not a whole food ingredient, and therefore has no conventional nutritional profile in terms of macronutrients, vitamins, or minerals. It is a secondary plant metabolite isolated primarily from Tithonia diversifolia (Mexican sunflower). Molecular formula: C20H26O7, molecular weight approximately 382.41 g/mol. As a sesquiterpene lactone, it contains an alpha-methylene-gamma-lactone functional group, which is considered the primary pharmacophore responsible for its bioactivity, including covalent binding to cysteine residues in target proteins. It is a lipophilic compound with moderate solubility in organic solvents (ethanol, DMSO, chloroform) and limited aqueous solubility, which directly impacts its bioavailability. No fiber, protein, carbohydrate, or micronutrient content is applicable. Concentration in Tithonia diversifolia leaf extracts has been reported in the microgram-to-milligram per gram dry weight range, though precise standardized concentrations vary by extraction method and plant part. Oral bioavailability data in humans is not established; absorption likely follows lipophilic compound kinetics with potential first-pass metabolism concerns. No dietary reference intake or recommended concentration exists as it is studied exclusively as a pharmacologically active isolated compound, not a dietary nutrient.

Preparation & Dosage

No clinically studied dosages are available due to the absence of human trials. In vitro data report an IC₅₀ of 0.0042 μg/mL against Trypanosoma brucei. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Curcumin, Resveratrol, Berberine, Green Tea Extract, Quercetin

Safety & Interactions

No human safety data, established dosage, or formal toxicology profile exists for isolated Tagitinin C, as all research remains at the preclinical stage. The alpha-methylene-gamma-lactone group is a known sensitizer and may cause contact dermatitis or allergic reactions, a class effect shared across sesquiterpene lactones such as parthenolide and artemisinin derivatives. Potential interactions with anticoagulants, immunosuppressants, or cytochrome P450-metabolized drugs cannot be ruled out given the compound's electrophilic reactivity and lack of pharmacokinetic data. Tagitinin C is contraindicated in pregnancy and lactation based on general precautionary principles for bioactive sesquiterpene lactones with cytotoxic potential.